Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
HIV Clinical Trials|June 20, 2003
Once-a-day HAART: dream or reality?Franco Maggiolo, Diego Ripamonti, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
AIDS (London, England)|April 26, 2007
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected womanDiego Ripamonti, Franco Maggiolo, Fredy Suter
Journal of Chromatographic Science|July 24, 2008
Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detectionDario Cattaneo, Franco Maggiolo, Diego Ripamonti, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 23, 2013
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimenGiorgio L Colombo, Sergio Di Matteo, Franco Maggiolo
AIDS (London, England)|January 16, 2018
Post-treatment controllers after treatment interruption in chronically HIV-infected patientsFranco Maggiolo, Elisa Di Filippo, Laura Comi, et al.
AIDS (London, England)|December 13, 2001
Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimensDiego Ripamonti, Claudio Arici, Franco Maggiolo, et al.
Journal of Medical Virology|May 20, 2014
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA)Roberto Rossotti, Luigi Fonte, Genny Meini, et al.
HIV Clinical Trials|March 15, 2005
Quadruple-drug induction HAART in advanced HIV infectionFranco Maggiolo, Diego Ripamonti, Annapaola Callegaro, et al.
AIDS (London, England)|April 13, 2004
Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patientsDiego Ripamonti, Claudio Arici, Patrizio Pezzotti, et al.
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
HIV Clinical Trials|June 20, 2003
Once-a-day HAART: dream or reality?Franco Maggiolo, Diego Ripamonti, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
AIDS (London, England)|April 26, 2007
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected womanDiego Ripamonti, Franco Maggiolo, Fredy Suter
Journal of Chromatographic Science|July 24, 2008
Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detectionDario Cattaneo, Franco Maggiolo, Diego Ripamonti, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 23, 2013
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimenGiorgio L Colombo, Sergio Di Matteo, Franco Maggiolo
AIDS (London, England)|January 16, 2018
Post-treatment controllers after treatment interruption in chronically HIV-infected patientsFranco Maggiolo, Elisa Di Filippo, Laura Comi, et al.
AIDS (London, England)|December 13, 2001
Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimensDiego Ripamonti, Claudio Arici, Franco Maggiolo, et al.
Journal of Medical Virology|May 20, 2014
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA)Roberto Rossotti, Luigi Fonte, Genny Meini, et al.
HIV Clinical Trials|March 15, 2005
Quadruple-drug induction HAART in advanced HIV infectionFranco Maggiolo, Diego Ripamonti, Annapaola Callegaro, et al.
AIDS (London, England)|April 13, 2004
Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patientsDiego Ripamonti, Claudio Arici, Patrizio Pezzotti, et al.
Pageof 17